Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Psychoneuroendocrinology. 2013 Sep 6;38(12):10.1016/j.psyneuen.2013.08.008. doi: 10.1016/j.psyneuen.2013.08.008

Figure 1. Relationship between each patient’s rating of current fatigue severity versus: A. DBI mRNA levels, and B. VIPR2 mRNA levels.

Figure 1

Open squares/broken line=CFS, filled diamonds/solid line=PCF. For DBI, this relationship is significant for both patient groups (r= −0.35 and −0.50, R2= .12 and .25, p<0.05 and p<0.005, respectively). For VIPR2, this relationship is significant for CFS (r= −.39, R2= .15, p<0.05) and non-significant for PCF (r= −0.25, R2= .06, p=0.16). PCF patients have lower group mean VIPR2 levels than the CFS group (p<0.001).